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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a variable course. Not uncommonly, IPF
patients are hospitalized for respiratory-related causes, including disease worsening. This study aimed to characterize the
prevalence, and economic and health care burden of IPF.
Methods: Retrospective insurance claims data collected yearly between January 1, 2009 and December 31, 2011, were
used to determine prevalence and calculate all-cause and respiratory-related resource utilization and costs. Patients had
at least one inpatient claim or two outpatient claims for IPF (ICD-9-CM code 516.3). Results for health care burden are
reported for the 2011 cohort (similar findings in 2009–2010). Costs are reported in 2011 US dollars ($).
Results: Patients with IPF had a mean age of 69.8–71.3 years. Overall prevalence for IPF was 28.8, 28.1 and 19.8 per
100,000 insured persons in 2009, 2010 and 2011. In each year, prevalence increased with age. In 2011, 37.7 % of patients
were hospitalized at least once for any cause; 19.5 % for respiratory-related reasons. Also in 2011, the mean number of
all-cause outpatient visits and respiratory-related office visits was 18.5 and 5.7 per patient, respectively. All-cause health
care costs in 2011 were $59,379 per patient; 36.6 % of costs ($21,732) were respiratory related.
Conclusions: The prevalence of IPF in this claims database increased with age, with a notable increase in those over
65 years. IPF is associated with a large economic and health care burden. Additional research is needed to determine
how such burden might be reduced.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic disease
in which normal lung parenchyma is replaced with
fibrotic tissue, leading to dyspnea, cough and impaired
lung function [1]. IPF predominantly occurs in older
adults [1] and the progressive nature of the disease re-
sults in a median survival time of approximately 3 years
from diagnosis [2, 3]. Commonly reported comorbid
conditions among IPF patients include pulmonary
hypertension, gastroesophageal reflux disease, obesity,
emphysema, cardiovascular conditions and obstructive
sleep apnea [4, 5]. IPF itself and these common comor-
bidities significantly impair health-related quality of life
among patients [6] and impose a substantial burden on
health care resources [5].
Although data are limited, compared with patients
without IPF, those with IPF require greater health care
resource utilization, have a greater number of comorbid-
ities [7, 8] and generate higher direct medical costs [7].
Consensus guidelines recommend lung transplantation
and long-term oxygen as potential therapies for IPF
[4]—both are costly treatments. The FDA recently ap-
proved pirfenidone and nintedanib for the treatment of
IPF; how these therapies affect resource utilization and
cost in a real-world setting is yet to be determined [9, 10].
IPF incidence rate and prevalence estimates vary
across studies because of differences in design and
data sources [11, 12]. The prevalence of IPF ranges
from 0.7 – 6.4 per 100,000 individuals in Taiwan to
27.9–63.0 per 100,000 in the USA, while incidence has
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been reported as 0.6–1.4 and 8.8–17.4 per 100,000
person-years, in Taiwan and the USA, respectively [13].
Because the incidence and prevalence of IPF is greater
among older citizens, with the US population aging [12–
14], it is expected that the economic burden and health
care resource utilization of IPF will likely increase in the
foreseeable future. Thus, there is a desperate need for im-
proved understanding of the burden of IPF on health care
systems. In this study, we used a commercial insurance
claims database to characterize the economic burden of
IPF by investigating health care resource utilization and
costs associated with patient management.
Methods
Data source
Data for this study were obtained from a large Health
Insurance Portability and Accountability Act (HIPAA) of
1996-compliant insurance claims database. The database
used was the Humedica (from Optum) database and ac-
cess was via a license agreement (not openly available).
The database provides information on medical and phar-
macy claims for approximately 30 million lives in the
USA. In this study, extracted data covered four geo-
graphical regions in the USA (Midwest, Northeast,
South and West). In compliance with HIPAA 1996, all
data were void of identifying information and therefore
the study is exempt from institutional review board
approval.
Inclusion criteria
This study included three cohorts, each formed by
capturing data spanning a 1 year period (January 1,
2009–December 31, 2009; January 1, 2010–December
31, 2010 and January 1, 2011–December 31, 2011
[Fig. 1]). To be included in a cohort, patients needed
at least one inpatient claim or two outpatient claims
with IPF as one of the listed diagnosis codes (Inter-
national Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] code 516.3) any-
time in that calendar year. Patients were required to
be continuously enrolled with the health plan in the
same calendar year and have no other type of inter-
stitial lung disease (ILD) diagnosis after their last IPF
claim in that calendar year.
Some patients may have had an IPF diagnosis for the
entire period (and are thus included in more than one of
the three cohorts), and other patients may have been diag-
nosed in the last month of a study period (e.g. December)
and were therefore included in the cohort for that entire
year. In 2012, the ICD-9 code for IPF changed from 516.3
to 516.31. Due to the possibility of coding errors in 2012
resulting from this change, the study was limited to 2009–
2011. For each year, insurance claims were extracted from
the database for all patients. Respiratory-related medical
claims were classified as those associated with ICD-9-CM
codes 460.xx–519.xx.
Resource utilization and costs
Total health care costs, non-pharmacy costs (including
inpatient and outpatient services costs) and pharmacy/
medication costs were analyzed for all-cause and
respiratory-related health care utilization. The number
of inpatient hospitalizations, emergency department
(ED) visits and physician office visits was also assessed.
Respiratory-related medication costs include all out-
patient pharmacy claims of respiratory therapy, oral anti-
biotics and all possible IPF medication. In these
analyses, medication costs were assessed and include
Fig. 1 Patient identification
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any of the eight groups of prescription medications used
to possibly treat IPF (corticosteroids, azathioprine, cyclo-
phosphamide, N-acetylcysteine, sildenafil, interferon-
gamma, bosentan, etanercept). No FDA-approved treat-
ments were available for IPF at the time of this study.
The usual physician specialty for IPF care was defined as
the physician specialty with the largest plurality of IPF
office visits (office visits with primary diagnosis of IPF)
with evaluation and management services. For some pa-
tients, there was no office visit meeting that definition
(e.g. with a primary IPF diagnosis) and they could not be
classified. In other patients, there were visits but the
physician specialty was not listed, and they could not be
classified either.
Prevalence estimates
Prevalence estimates for each year were calculated based
on the number of patients with an ICD-9-CM code for
IPF (516.3) and no other type of ILD after their last IPF
claim as the numerator. The number of members con-
tinuously enrolled in a given calendar year, regardless of
diagnosis, was used as the denominator.
Statistical analysis
Descriptive statistics were generated for baseline data.
Means and standard deviations are reported for continu-
ous variables, and counts and percentages for categorical
variables. Economic and health care burden are reported
for the 2011 cohort (findings were similar in 2009–2010).
Estimated costs are reported in 2011 US dollars ($). The
Charlson Comorbidity Index, which includes a total of 22
conditions and can predict 10-year mortality risks [15],
was used to evaluate the prognosis for the patient popula-
tions, in which a range of comorbid conditions were
present. Each condition was assigned a score of one, two,
three or six, depending on its association with the risk of
dying. Scores were summed to provide a total score pre-
dictive of mortality. All analyses were performed using
SAS® version 9.4.
Demographics are reported for all 3 years and for
prevalence estimates, but only 2011 data were used for
the utilization analyses. All figures and tables show data
for all 3 years.
Results
Demographics
The study population consisted of 1191, 1292 and 1136
IPF patients in 2009, 2010 and 2011, respectively (Fig. 1).
Patients’ mean age ranged from 69.8 to 71.3 years, and the
population was equally balanced by gender. The majority
of patients (39.7–42.3 %) originated from the Southern re-
gion of the USA, compared with 12–15 % from the North-
east, 18–23 % from the West, and 24–25 % from the
Midwest (Table 1). In each annual cohort, the usual
physician specialty providing IPF care was a pulmonolo-
gist in approximately half of the population (49.2–50.5 %);
the physician specialty providing care was unknown in ap-
proximately 30 % of cases. The overall Charlson Comor-
bidity Index remained constant at 3.2 over the three
periods (P = 0.917). The study population had a high
(mean of six) number of chronic conditions and co-
morbidities contributing to this score (Table 2), in-
cluding chronic obstructive pulmonary disease (53.4–
56.9 %), cardiovascular conditions (48.1–51.1 %) and
bacterial pneumonia (24.9–30.9 %).
Prevalence
Overall, IPF prevalence was 28.8 (1191/4,138,796), 28.1
(1292/4,595,629) and 19.8 (1136/5,748,328) per 100,000
insured persons in 2009, 2010 and 2011, respectively.
Similar values were observed between genders (Fig. 2).
Prevalence increased for patients aged ≥65 years, and
the highest prevalence was observed among those
≥80 years old: 185.5 (338/182,231), 179.4 (369/205,708)
and 165.9 (347/209,135) per 100,000 insured persons in
2009, 2010 and 2011, respectively; Fig. 3).
Diagnosis and treatment
In 2011, about half of patients had a diagnostic test per-
formed (either lung biopsy [7.3 %] or computed tomog-
raphy of the thorax [46.5 %]) consistent with an attempt
to confirm a diagnosis of IPF. Use of oxygen at home
was observed in 52.6 % of patients; 44.6 % were treated
with oral corticosteroids and 1.7 % had a lung trans-
plant. A total of 12.1 % of patients participated in pul-
monary rehabilitation.
Table 1 Patient demographics
2009 2010 2011
(N = 1191) (N = 1292) (N = 1136)
Age, years, mean (SD) 69.8 (11.1) 70.0 (11.4) 71.3 (10.6)
Female, n (%) 600 (50.4) 671 (51.9) 558 (49.1)
Region, n (%)
Midwest 297 (24.9) 309 (23.9) 279 (24.6)
Northeast 152 (12.8) 160 (12.4) 171 (15.1)
South 473 (39.7) 545 (42.2) 481 (42.3)
West 269 (22.6) 278 (21.5) 205 (18.0)
IPF care specialtya, n (%)
Pulmonologist 586 (49.2) 652 (50.5) 553 (48.7)
Primary care 213 (17.9) 217 (16.8) 187 (16.5)
Other (<2 % each) 61 (5.1) 52 (4.0) 43 (3.8)
Unknown 331 (27.8) 371 (28.7) 353 (31.1)
IPF = idiopathic pulmonary fibrosis
aIPF care specialty defined as the physician specialty with the largest plurality
of IPF office visits with evaluation and management services. For some
patients, there was no office visit meeting that definition and others whose
physician specialty was not listed, these were classified as unknown
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Health care resource use and costs
There was no significant difference over the three pe-
riods (P = 0.690) in the mean number of all-cause out-
patient clinic visits, which in 2011 was 18.5 per patient.
Similarly, there was no significant difference over time
in the mean number of clinic visits specifically due to
respiratory-related conditions (5.7 per patient in 2011,
P = 0.654). A total of 37.7 % of patients were hospital-
ized at least once due to any cause, and 7.7 % were
hospitalized (for any cause) at least three times. Over-
all, 30.5 % of patients visited the ED on at least one
occasion for any cause. For respiratory-related condi-
tions, 19.5 % of patients (n = 221) were hospitalized
and 15.8 % (n = 179) visited the ED at least once
(Fig. 4). The mean annual all-cause health care cost
was $59,379 per patient in 2011, with 36.6 % of the
total all-cause health care costs spent on respiratory-
related care (Fig. 5). Non-medication health care costs
(for any condition) were $52,716 per patient. The ma-
jority of this was for inpatient ($38,032) rather than
outpatient services ($14,684). Non-medication costs for
respiratory-related conditions accounted for 37.2 % of
health care cost. The main medications costs were for
generic corticosteroids, which were used in approximately
60 % of patients, with no significant differences in use over
the three periods (P = 0.787).
Discussion
IPF is a severe, chronic condition that primarily affects
patients older than 60 years of age, who often have other
comorbidities and who require substantial health care re-
sources. In this study, we used a large, de-identified insur-
ance claims database to identify three annual cohorts of IPF
patients. The heightened presence of chronic conditions
and comorbidities in the population was reflected in the
10-year Charlson Comorbidity Index score of 3.2. Overall,
IPF patients were found to be frequent health care service
users, with nearly 19 outpatient visits per year. More than
one-third of patients were hospitalized—and approximately
30 % visited the ED—at least once per year. During that
time period, the provision of inpatient and outpatient care
amounted to a total annual cost of approximately $60,000
per patient, with about one-third of this spent on
respiratory-related care.
A high level of variability exists in epidemiologic
reports of incidence and prevalence in IPF, most likely
Table 2 Diagnosis of comorbidities in patients with IPF
2009 2010 2011
(N = 1191) (N = 1292) (N = 1136)
CCI, mean (SD) 3.2 (2.7) 3.2 (2.7) 3.2 (2.7)
Number of chronic conditions, mean (SD) 5.9 (2.0) 5.9 (2.0) 5.9 (2.0)
Conditions, n (%)
COPD (including emphysema) 636 (53.4) 692 (53.6) 646 (56.9)
Cardiovascular conditions 573 (48.1) 626 (48.5) 581 (51.1)
Bacterial pneumonia 364 (30.6) 380 (29.4) 351 (30.9)
Lung cancer 49 (4.1) 39 (3.0) 43 (3.8)
Pulmonary hypertension 101 (8.5) 131 (10.1) 79 (7.0)
GERD 332 (27.9) 378 (29.3) 336 (29.6)
Obstructive sleep apnea 176 (14.8) 199 (15.4) 169 (14.9)
Obesity 95 (8.0) 106 (8.2) 87 (7.7)
CCI = Charlson Comorbidity Index, COPD = chronic obstructive pulmonary disease, GERD = gastroesophageal reflux
Cardiovascular conditions included ischemic heart disease, myocardial infarction, congestive heart failure, pulmonary hypertension
Fig. 2 Prevalence of IPF by gender
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due to differences in diagnostic testing and case def-
inition, as well as differences in study populations
and study design [4, 5, 11]. However, it is generally
agreed that prevalence is increasing due to the aging
of the population and improved awareness and earlier
diagnosis of the condition [13, 14]. In a recent review
of 15 studies investigating IPF prevalence in the
USA, the authors reported values from 14 to 27.9
cases per 100,000 population [16]. Other data con-
firm a higher prevalence among patients aged 75 years
or older (67.4 per 100,000 persons) compared with
people in the 18–34-year age range (0.8 per 100,000
persons) [12]. In our study, overall prevalence ranged
from 19.8 to 28.8 per 100,000 insured persons and
was lowest in 2011; when data were analyzed over
the 5-year age group, prevalence was highest in pa-
tients aged 80 years or over (165.9–185.5 per 100,000
insured persons).
However, health care utilization and costs were similar
across all 3 years. An increase in the total number of
insured people (from 4.1 million in 2009 to 5.7 million
in 2011)—the denominator—is likely to have contributed
to the lower prevalence of IPF in 2011, since the num-
bers of IPF patients (the numerator) were similar over
the 3-year period. In fact, the higher number of insured
people in 2011 was composed of a large number of indi-
viduals from the youngest age group (unlikely to have
IPF). The number of those aged between 12 and 44 years
differed from 1.7 and 1.9 million in 2009 and 2010, to
2.5 million in 2011. Data from the Centers of Disease
Control and Progression support our observation, and
show that the proportion of uninsured adults aged
19–25 years fell from 35.6 % in the third quarter of
2010 to 27.0 % in the fourth quarter of 2012 [17]. In
addition, an analysis of IPF in US Medicare beneficiaries
aged 65 years or above between the years 2000–2011
Fig. 3 Prevalence of IPF according to age
Fig. 4 Health care resource utilization according to all-cause or respiratory-related conditions
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revealed that the incidence of IPF remained stable (overall
estimate 93.7 cases per 100,000 person-years), while the
prevalence increased from 202.2 to 494.5 cases per
100,000 person-years over this period [18].
The prevalence of IPF is usually reported as higher
among males [19–21]; however, we observed no differ-
ence by gender. This is possibly due to more women
accessing care, but we are unable to verify this suppos-
ition. In general, women are more likely to seek health
care services than men [22–24], and women are more
willing to look after themselves [23]. As in previously
published studies, in which IPF prevalence has been re-
ported to increase with age (and the highest rates ob-
served in patients over 75 years old) [16], we observed
an increase in IPF prevalence with age in this claims
database, with a notable rise in those older than 65 years.
We observed that most cases (39.7–42.3 %) derived from
the southern area of the USA, a finding that reflects
other real-world health care experiences. For example,
data from Optum Payer lists, covering over 150 million
individuals across all payer types, reveal that 33–46 % of
claims are from the Southern area of the US, approxi-
mately double those coming from the West, Midwest,
and Northeast states [25]. Given the consistency of these
observations, we suggest that this phenomenon is likely
due to distribution of the source population rather than
regional differences in disease prevalence.
Few previous studies have reported on the economic
burden of IPF. Most recently, Wu et al. [8] found that
IPF patients were more likely to use health care re-
sources than non-IPF patients (number of hospitaliza-
tions 0.63 vs. 0.31, emergency room visits 0.62 vs. 0.48
and outpatient visits 5.7 vs. 3.1 per person-year). Simi-
larly, Collard et al. [7] reported that the all-cause hos-
pital admission rate (0.5 per person-year) and outpatient
visit rate (28.0 per person-year) for IPF patients were
both nearly two-fold higher than in controls. Total direct
costs for patients with IPF were approximately $26,000
per person-year. Differences in case-finding and
expense-inclusion likely account for differences in cost
between that and our study [16]. Rather than limiting
expenses to those incurred for IPF alone, to help reflect
the true cost of care for these patients, we included costs
and health care utilization for any cause and, for other
analyses, for any respiratory-related condition (including
IPF, bronchitis, pneumonia, etc.). These data reflect ac-
tual patient care rather than a clinical trial situation. In
clinical practice, patients are often given other diagnoses
(e.g. myocardial ischemia, asthma, chronic obstructive
pulmonary disease [COPD], obesity, ILD) and are evalu-
ated by more than two practitioners before ultimately
being correctly diagnosed with IPF. Some patients in our
study may have been initially diagnosed with a condition
other than IPF and had the diagnosis changed to IPF
after additional evaluation.
Database analyses come with inherent limitations, and
use of secondary data, without direct involvement of the
patient or physician, may decrease confidence in the con-
clusions drawn [26, 27]. Insurance claims data depend on
professional ICD coding, and, given the complexity of the
disease process, it must be recognized that accurate diag-
nosis of IPF can be challenging [27, 28]. In the clinical
setting, some cases may be misdiagnosed, and coding pat-
terns may vary between professionals. In this study, the
physician specialty for IPF care was pulmonologist in ap-
proximately 50 % of patients, and the other half were seen
by a primary health care physician or a physician whose
specialty was not recorded, for most of their IPF care
visits. It is indeed likely that some patients whose practi-
tioners were recorded as unknown may actually have seen
a pulmonologist. Guidelines recommend high-resolution
computed tomography (HRCT) of the lungs and/or surgi-
cal lung biopsy to diagnose IPF [4]. In this study, the lower
than expected number of patients with a diagnostic test is
a reflection of the cross-sectional study design; it is likely
that patients had a HRCT scan conducted at the time of
their diagnosis (e.g. diagnosed with IPF prior to 2009), but
this may have been outside the study period.
Fig. 5 Health care costs (medication and non-medication) due to all-cause or respiratory-related conditions
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Furthermore, approximately 50 % of IPF patients also
had a diagnosis of COPD, including emphysema; whether
these were incorrect diagnoses in patients who previously
smoked (but did not have COPD) or correctly coded co-
morbid conditions cannot be determined from the available
data. To help reduce the effect of coding inconsistencies,
data on all-cause and respiratory-related conditions were
considered. This included individuals with at least 1 in-
patient claim or two outpatient claims with IPF as one of
the diagnosis codes, in hopes of capturing all patients with
IPF, including those who may have been misdiagnosed. To
limit miscoding, patients who had a non-IPF ILD claim
after the last IPF claim in that calendar year were excluded
from the analysis. Similar criteria have been used in previ-
ous studies [7, 8, 18].
Because the ICD-9 code for IPF changed from 516.3
to 516.31 in 2012, the current analysis was limited to
2009–2011 to further limit possible coding errors.
Other limitations include the cross-sectional study de-
sign and the fact that patients were not required to
have IPF for the entire calendar year; thus, given that
some patients may only have started to incur costs later
in the year, the total economic burden of disease may
be underestimated. A cross-sectional view of patients
with IPF offers a true-to-life picture of what might be
expected in any given year in which some patients are
diagnosed early and others later in the year.
Conclusion
IPF presents a large burden on health care utilization
resources. Additional research is needed to determine
whether and how this burden might be reduced.
Abbreviation
CCI: Charlson comorbidity index; ED: Emergency department; HIPAA: Health
insurance portability and accountability act; ICD-9-CM: International
classification of diseases, ninth revision, clinical modification; ILD: Interstitial
lung disease; IPF: Idiopathic pulmonary fibrosis.
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